EA202190799A1 - Макромолекулярные пролекарства на полимерной основе - Google Patents
Макромолекулярные пролекарства на полимерной основеInfo
- Publication number
- EA202190799A1 EA202190799A1 EA202190799A EA202190799A EA202190799A1 EA 202190799 A1 EA202190799 A1 EA 202190799A1 EA 202190799 A EA202190799 A EA 202190799A EA 202190799 A EA202190799 A EA 202190799A EA 202190799 A1 EA202190799 A1 EA 202190799A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- prolectives
- polymer
- based macromolecular
- macromolecular
- macromolecular prodrugs
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732199P | 2018-09-17 | 2018-09-17 | |
| PCT/US2019/051457 WO2020061007A1 (en) | 2018-09-17 | 2019-09-17 | Polymer-based macromolecular prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190799A1 true EA202190799A1 (ru) | 2021-06-22 |
Family
ID=69887739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190799A EA202190799A1 (ru) | 2018-09-17 | 2019-09-17 | Макромолекулярные пролекарства на полимерной основе |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11253603B2 (https=) |
| EP (1) | EP3852793B1 (https=) |
| JP (1) | JP7546552B2 (https=) |
| KR (1) | KR20210072002A (https=) |
| CN (2) | CN112996533B (https=) |
| AU (1) | AU2019344783B2 (https=) |
| CA (1) | CA3112778A1 (https=) |
| EA (1) | EA202190799A1 (https=) |
| MX (1) | MX2021003116A (https=) |
| WO (1) | WO2020061007A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3112778A1 (en) * | 2018-09-17 | 2020-03-26 | The Children's Hospital Of Philadelphia | Polymer-based macromolecular prodrugs |
| CN115443947B (zh) * | 2022-10-12 | 2023-11-21 | 江苏省人民医院（南京医科大学第一附属医院） | 高血压动物模型的制备方法 |
| WO2025101904A1 (en) * | 2023-11-08 | 2025-05-15 | The Children's Hospital Of Philadelphia | Norepinephrine transporter-targeted prodrugs for cancer therapy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999052861A1 (de) | 1998-04-09 | 1999-10-21 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik |
| JP2002255821A (ja) | 2001-03-06 | 2002-09-11 | Yakult Honsha Co Ltd | 抗癌剤耐性癌に対する治療剤 |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US20040258754A1 (en) * | 2003-06-18 | 2004-12-23 | Valery Alakhov | Compositions for oral administration of camptothecin and its analogs |
| CA2537336C (en) | 2003-09-17 | 2013-02-26 | Nektar Therapeutics Al, Corporation | Multi-arm polymer prodrugs |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| WO2005042539A1 (en) * | 2003-10-29 | 2005-05-12 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| WO2007106549A2 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Method for treating brain cancer |
| BRPI0716808A2 (pt) * | 2006-09-15 | 2013-11-05 | Enzon Pharmaceuticals Inc | Ligantes poliméricos baseados em lisina |
| US20090074074A1 (en) | 2007-06-29 | 2009-03-19 | The Hong Kong University Of Science And Technology | Multiple description encoder and decoder for transmitting multiple descriptions |
| AU2009282413B2 (en) * | 2008-08-11 | 2014-07-17 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| LT2349346T (lt) | 2008-09-23 | 2019-09-25 | Nektar Therapeutics | Kamptotecino provaistų (pvz., peg-irinotekano) metronominio dozavimo būdas |
| KR20110075029A (ko) | 2008-10-21 | 2011-07-05 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료 |
| CN101385860B (zh) * | 2008-10-31 | 2011-11-02 | 美国草药泉有限责任公司 | 喜树碱及其衍生物的非线性聚乙二醇前药 |
| US20120171201A1 (en) | 2009-07-22 | 2012-07-05 | Enzon Pharmaceuticals, Inc. | Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| PT2501413T (pt) | 2009-11-18 | 2019-07-10 | Nektar Therapeutics | Formas de sal de ácido de conjugados de polímero-fármaco |
| US20140371258A1 (en) | 2010-12-17 | 2014-12-18 | Nektar Therapeutics | Water-Soluble Polymer Conjugates of Topotecan |
| CN102626518B (zh) * | 2012-05-09 | 2014-05-28 | 中国药科大学 | 一种包载难溶性药物的泊洛沙姆/两亲性多糖混合胶束的制备和应用 |
| WO2014085571A1 (en) | 2012-11-28 | 2014-06-05 | Nektar Therapeutics | Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor |
| WO2014194289A1 (en) | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| MX371201B (es) | 2013-10-04 | 2020-01-22 | Prolynx Llc | Conjugados de liberación lenta de sn-38. |
| WO2015191583A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| US11324827B2 (en) | 2014-10-01 | 2022-05-10 | Xiamen Sinopeg Biotech Co., Ltd. | Multifunctionalized polyethylene glycol derivative and preparation method therefor |
| CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| US20200163956A1 (en) | 2016-09-06 | 2020-05-28 | Cerebral Therapeutics LLC | Direct brain administration of chemotherapeutics to the csf for patients with primary and secondary brain tumors |
| KR102279429B1 (ko) | 2017-04-21 | 2021-07-20 | 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. | 멀티 암 표적 항암 콘쥬게이트 |
| JP7381083B2 (ja) | 2017-09-08 | 2023-11-15 | フォスプラティン テラピューティクス インコーポレイテッド | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 |
| WO2019090141A1 (en) | 2017-11-02 | 2019-05-09 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3112778A1 (en) | 2018-09-17 | 2020-03-26 | The Children's Hospital Of Philadelphia | Polymer-based macromolecular prodrugs |
| CN111603567B (zh) | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
-
2019
- 2019-09-17 CA CA3112778A patent/CA3112778A1/en active Pending
- 2019-09-17 MX MX2021003116A patent/MX2021003116A/es unknown
- 2019-09-17 WO PCT/US2019/051457 patent/WO2020061007A1/en not_active Ceased
- 2019-09-17 CN CN201980060783.3A patent/CN112996533B/zh active Active
- 2019-09-17 US US16/969,790 patent/US11253603B2/en active Active
- 2019-09-17 JP JP2021514531A patent/JP7546552B2/ja active Active
- 2019-09-17 EP EP19863240.8A patent/EP3852793B1/en active Active
- 2019-09-17 CN CN202510008384.XA patent/CN119950749A/zh active Pending
- 2019-09-17 KR KR1020217011264A patent/KR20210072002A/ko active Pending
- 2019-09-17 EA EA202190799A patent/EA202190799A1/ru unknown
- 2019-09-17 AU AU2019344783A patent/AU2019344783B2/en active Active
-
2022
- 2022-02-11 US US17/670,218 patent/US11642414B2/en active Active
-
2023
- 2023-04-27 US US18/140,289 patent/US12311028B2/en active Active
-
2025
- 2025-05-13 US US19/206,574 patent/US20250387496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020061007A1 (en) | 2020-03-26 |
| CN119950749A (zh) | 2025-05-09 |
| CA3112778A1 (en) | 2020-03-26 |
| JP2022501341A (ja) | 2022-01-06 |
| CN112996533B (zh) | 2025-01-10 |
| NZ773863A (en) | 2024-10-25 |
| EP3852793A4 (en) | 2022-07-13 |
| US20210000967A1 (en) | 2021-01-07 |
| US20230414766A1 (en) | 2023-12-28 |
| US12311028B2 (en) | 2025-05-27 |
| CN112996533A (zh) | 2021-06-18 |
| EP3852793C0 (en) | 2025-11-19 |
| JP7546552B2 (ja) | 2024-09-06 |
| KR20210072002A (ko) | 2021-06-16 |
| EP3852793B1 (en) | 2025-11-19 |
| EP3852793A1 (en) | 2021-07-28 |
| US11642414B2 (en) | 2023-05-09 |
| AU2019344783A1 (en) | 2021-04-08 |
| US20220160886A1 (en) | 2022-05-26 |
| US20250387496A1 (en) | 2025-12-25 |
| MX2021003116A (es) | 2021-05-14 |
| US11253603B2 (en) | 2022-02-22 |
| AU2019344783B2 (en) | 2025-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126442T1 (el) | Αντισωματα anti-ntb-a και σχετικες συνθεσεις και μεθοδοι | |
| CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1124568T1 (el) | Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης | |
| CY1123441T1 (el) | Μορια με ειδικοτητα στα cd45 και cd79 | |
| CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| EA201992780A1 (ru) | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания | |
| EA201690744A1 (ru) | Конъюгаты белок-полимер-лекарственное средство | |
| PH12019502333A1 (en) | Targeted compositions | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| CY1121870T1 (el) | Anti-egfrviii αντισωματα και χρησεις αυτων | |
| EA202090410A1 (ru) | АГОНИСТЫ Toll-ПОДОБНОГО РЕЦЕПТОРА 7 (TLR7), ИМЕЮЩИЕ ПИРИДИНОВЫЙ ИЛИ ПИРАЗИНОВЫЙ ФРАГМЕНТ, ИХ КОНЪЮГАТЫ, ПРИМЕНЕНИЯ И СПОСОБЫ С НИМИ | |
| CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
| MX2023001582A (es) | Conjugados proteina-polimero-farmaco. | |
| MX2023002599A (es) | Conjugados de compuestos de tubulisina cuaternizada. | |
| CY1121710T1 (el) | Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας | |
| EA201990470A1 (ru) | Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства | |
| PE20160190A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados | |
| EA201291194A1 (ru) | Индолы | |
| NZ746680A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| EA201991196A1 (ru) | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования |